Bladder Preservation Radiotherapy
Trimodality Therapy (TMT) combining maximal TURBT, radiosensitizing chemotherapy, and precise radiation to cure bladder cancer without cystectomy.
Curing muscle-invasive bladder cancer while keeping your natural, functioning bladder.
For patients diagnosed with muscle-invasive bladder cancer (MIBC), radical cystectomy (complete surgical removal of the bladder with a permanent urinary stoma bag or neobladder) is not the only curative path.
Trimodality Therapy (TMT) is a guideline-endorsed curative alternative combining maximum endoscopic tumor resection (TURBT), followed by concurrent radiosensitizing chemotherapy and image-guided radiotherapy.
Long-term clinical trials from Massachusetts General Hospital and European centers demonstrate equal 5-year survival rates between TMT and radical cystectomy, allowing over 70-80% of patients to preserve their native, normally functioning bladder.
Key Clinical Considerations in Your Consultation
Every recommendation is customized according to staging scans, pathology markers, and patient priorities.
Candidacy assessment for bladder preservation (unifocal disease, good bladder capacity)
Coordination with urologists for maximal transurethral resection (TURBT)
Daily image-guided VMAT radiotherapy with full/empty bladder planning
Concurrent radiosensitizing chemotherapy regimens
Rigorous post-treatment surveillance cystoscopy protocols
Comprehensive second opinion before undergoing radical cystectomy
Discuss Bladder Preservation Radiotherapy
Bring biopsy reports, recent PET/CT or MRI scans, and operative summaries for a comprehensive consultation.